Endobronchial Ultrasound (EBUS) Biopsy Market Size, Share and Growth Outlook, 2026

Endobronchial Ultrasound (EBUS) Biopsy Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Endobronchial Ultrasound (EBUS) Biopsy Market size is forecast to increase from $178.01 Million in 2026 to $279.47 Million in 2034 at a CAGR of 5.8% between 2026 and 2034.

The Endobronchial Ultrasound (EBUS) Biopsy market report provides detailed analysis and outlook of Endobronchial Ultrasound (EBUS) Biopsy segments including By Product Type (EBUS Scopes, EBUS Needles, Ultrasound Processors & Imaging Systems, Biopsy Forceps & Cytology Brushes, Accessories ), By Procedure (EBUS-Transbronchial Needle Aspiration, EBUS-Guided Biopsy), By Application (Lung Cancer Diagnosis and Staging, Infection Diagnosis, Sarcoidosis Detection, Other Respiratory Disorders), By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Pulmonary Clinics, Diagnostic Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Endobronchial Ultrasound (EBUS) Biopsy Industry Overview

Balloon-Less EBUS Bronchoscope Design Improving Procedural Efficiency and Infection Control

The endobronchial ultrasound (EBUS) biopsy industry is advancing through device innovations aimed at improving procedural efficiency and reducing infection risks. Fujifilm Healthcare Americas Corporation launched the EB-710US ultrasound bronchoscope featuring a balloon-less design that eliminates the need for manual balloon attachment during procedures. This innovation reduces preparation time while addressing infection risks associated with biofilm formation, streamlining workflow efficiency in bronchoscopy suites and improving overall procedural safety in EBUS-guided sampling.

Artificial Intelligence Enhancing Real-Time EBUS Diagnostic Accuracy

AI integration is transforming EBUS biopsy procedures by supporting real-time image interpretation and decision-making during tissue sampling. The AI-CEMA system has demonstrated strong performance in multicenter validation studies involving over 1,000 thoracic lymph nodes and more than 250 live clinical cases. With an AUC of 0.84 for distinguishing benign from malignant lymph nodes, the system achieves diagnostic accuracy comparable to experienced interventional pulmonologists. This supports improved targeting during transbronchial needle aspiration and enhances procedural precision in lung cancer staging workflows.

Robotic-Assisted Bronchoscopy Combined with EBUS Imaging for Complex Lesion Access

The integration of shape-sensing robotic-assisted bronchoscopy (ssRAB) with radial endobronchial ultrasound (rEBUS) is expanding the diagnostic reach of minimally invasive pulmonary procedures. Long-term multicenter data from the PRECIsE study demonstrates improved catheter stability and lesion accessibility in small pulmonary nodules ranging from 10 to 30 mm, particularly in sub-segmental airways. These systems are reducing reliance on cone-beam CT guidance and improving diagnostic yield in complex lung lesion sampling, supporting broader adoption of robotic-assisted bronchoscopic platforms.

Deep Learning-Driven Cytology Support for EBUS-TBNA Procedures

Advanced deep learning models are being integrated into EBUS-transbronchial needle aspiration (EBUS-TBNA) workflows to enhance cytological interpretation. Modified VGG16 neural networks trained on thousands of ultrasound samples have achieved diagnostic accuracy exceeding 75%, enabling automated detection of malignant patterns that may be difficult to identify visually. This technology supports community-level healthcare facilities lacking rapid on-site evaluation (ROSE) cytopathology services, improving early-stage lung cancer diagnosis and biopsy accuracy.

Endobronchial Ultrasound (EBUS) Biopsy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Endobronchial Ultrasound (EBUS) Biopsy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Olympus Corporation, FUJIFILM Holdings Corporation, Boston Scientific Corporation, Cook Group Incorporated, GE HealthCare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Medi-Globe GmbH, Ace Medical Devices, Praxis Medical Devices. The Endobronchial Ultrasound (EBUS) Biopsy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Endobronchial Ultrasound (EBUS) Biopsy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Endobronchial Ultrasound (EBUS) Biopsy Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Endobronchial Ultrasound (EBUS) Biopsy companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Endobronchial Ultrasound (EBUS) Biopsy markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Endobronchial Ultrasound (EBUS) Biopsy Market Competitive Benchmarking and Company Analysis

Leading companies in Endobronchial Ultrasound (EBUS) Biopsy industry include- Olympus Corporation, FUJIFILM Holdings Corporation, Boston Scientific Corporation, Cook Group Incorporated, GE HealthCare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Medi-Globe GmbH, Ace Medical Devices, Praxis Medical Devices. The Endobronchial Ultrasound (EBUS) Biopsy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Endobronchial Ultrasound (EBUS) Biopsy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Endobronchial Ultrasound (EBUS) Biopsy market remains one of the strongest-performing segments in the country.
The US Endobronchial Ultrasound (EBUS) Biopsy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Endobronchial Ultrasound (EBUS) Biopsy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Endobronchial Ultrasound (EBUS) Biopsy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Endobronchial Ultrasound (EBUS) Biopsy markets

Canada's strong Endobronchial Ultrasound (EBUS) Biopsy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Endobronchial Ultrasound (EBUS) Biopsy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Endobronchial Ultrasound (EBUS) Biopsy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Endobronchial Ultrasound (EBUS) Biopsy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Endobronchial Ultrasound (EBUS) Biopsy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Endobronchial Ultrasound (EBUS) Biopsy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Endobronchial Ultrasound (EBUS) Biopsy market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Endobronchial Ultrasound (EBUS) Biopsy sales through 2034

France Endobronchial Ultrasound (EBUS) Biopsy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Endobronchial Ultrasound (EBUS) Biopsy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Endobronchial Ultrasound (EBUS) Biopsy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Endobronchial Ultrasound (EBUS) Biopsy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Endobronchial Ultrasound (EBUS) Biopsy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Endobronchial Ultrasound (EBUS) Biopsy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Endobronchial Ultrasound (EBUS) Biopsy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Endobronchial Ultrasound (EBUS) Biopsy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Endobronchial Ultrasound (EBUS) Biopsy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Endobronchial Ultrasound (EBUS) Biopsy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Endobronchial Ultrasound (EBUS) Biopsy Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Endobronchial Ultrasound (EBUS) Biopsy Market Segmentation

By Product Type
EBUS Scopes
EBUS Needles
Ultrasound Processors & Imaging Systems
Biopsy Forceps & Cytology Brushes
Accessories
By Procedure
EBUS-Transbronchial Needle Aspiration
EBUS-Guided Biopsy
By Application
Lung Cancer Diagnosis and Staging
Infection Diagnosis
Sarcoidosis Detection
Other Respiratory Disorders
By End-User
Hospitals
Ambulatory Surgical Centers
Specialty Pulmonary Clinics
Diagnostic Centers

Top Companies in Endobronchial Ultrasound (EBUS) Biopsy Industry

Olympus Corporation
FUJIFILM Holdings Corporation
Boston Scientific Corporation
Cook Group Incorporated
GE HealthCare Technologies Inc.
Siemens Healthineers AG
Koninklijke Philips N.V.
Medi-Globe GmbH
Ace Medical Devices
Praxis Medical Devices

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025